Palisade Bio
PALI
7 hedge funds and large institutions have $527K invested in Palisade Bio in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
8% more capital invested
Capital invested by funds: $489K → $527K (+$38K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
13% less funds holding
Funds holding: 8 → 7 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$195K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$105K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$131K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.59K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$9K |
| 4 |
HF
HRT Financial
New York
|
-$8K |
| 5 |
VF
Virtu Financial
New York
|
-$3.19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $229K | +$195K | +61 | +235% |
|
|
2
Renaissance Technologies
New York
| $152K | -$131K | -41 | -41% |
|
|
3
HighTower Advisors
Chicago,
Illinois
| $87K | +$105K | +33 | New |
|
4
Bank of New York Mellon
New York
| $28K | – | – | – |
|
|
VF
5
Virtu Financial
New York
| $17K | -$3.19K | -1 | -14% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $12K | +$16K | +5 | New |
|
7
BlackRock
New York
| $2K | – | – | – |
|
|
HF
8
HRT Financial
New York
| – | -$8K | -3 | Closed |
|
|
9
Northern Trust
Chicago,
Illinois
| – | -$9K | -3 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$9.59K | -3 | Closed |
|
PALI Hedge Fund Activity: Q3 2020 in Review
7 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q3 2020, worth a combined $527K — up 7.8% from $489K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PALI and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Sabby Management, adding an estimated $195K. The largest seller was Renaissance Technologies, cutting an estimated $131K.
- 7 institutional investors held Palisade Bio (PALI) as of Q3 2020, down from 8 in Q2 2020.
- Funds reported $527K of Palisade Bio stock for Q3 2020, up 7.8% quarter-over-quarter.
- 2 funds opened new Palisade Bio positions in Q3 2020 and 3 closed out, a net change of -1 holder.
- The largest Palisade Bio buyer in Q3 2020 was Sabby Management, an estimated $195K added.
- The largest Palisade Bio seller in Q3 2020 was Renaissance Technologies, an estimated $131K sold.
Based on aggregated 13F filings for Q3 2020.